✨ Free AI Report
Arcellx, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Arcellx, Inc.
Company Research

Arcellx, Inc.: Business Overview, Financials & Competitive Analysis

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. The company's core innovation centers on its ...

Analyst-debate audio for Arcellx, Inc.

AskCyborg analysts argue the bull and bear cases for Arcellx, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
8/ 10Strong

Cyborg Score thesis

Rare clinical-stage biotech acquisition by major pharma at premium valuations signals transformative CAR-T platform success...

Read the full analyst-debate transcript →
Industry Biotechnology - Immunotherapy / Cell Therapy
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Arcellx, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Arcellx, Inc. Overview

Pro stress-test →

Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. The company's core innovation centers on its proprietary D-Domain Affinity Protein T-cell (DAPTI™) platform, which offers a differentiated approach to CAR-T cell therapies with enhanced safety and durability profiles.

Strategic Profile

Pro stress-test →

Arcellx is being acquired by Gilead in a $7.8B deal valued at $115 per share plus a $5 CVR tied to $6B anito-cel sales, with an FDA decision date of December 23, 2026 for its lead myeloma CAR-T therapy. The strategic collaboration with Kite Pharma (Gilead subsidiary) involves co-development and co-commercialization of anito-cel, under which Arcellx received substantial upfront payments and is eligible for future milestone payments.

Competitive Landscape

Pro stress-test →

Competitors include AbelZeta, Allogene Therapeutics, Senti Bio, Poseida Therapeutics, and Amgen. Arcellx differentiates through its proprietary D-Domain synthetic binder technology, which aims to reduce toxicity and enhance durability versus traditional single-chain variable fragment CAR-T approaches. The Gilead acquisition positions Arcellx as a fully-backed competitor with major commercial infrastructure.

Industry Context

Arcellx, Inc. operates in Biotechnology - Immunotherapy / Cell Therapy.

Key facts

Founded: 2014 · Headquarters: Redwood City, California · Revenue: $35.9M · Market cap: $6.65B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Arcellx, Inc..

  • Acquisition by Gilead signals exceptional validation of Arcellx's proprietary D-Domain technology and clinical CAR-T approach
  • FDA decision on lead candidate anito-cel scheduled for December 23, 2026 represents critical near-term catalyst
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Gilead Sciences announces $7.8B acquisition of Arcellx at $115/share plus $5 CVR
  • December 2025Continued clinical progress on Phase 2 anitocabtagene autoleucel data for multiple myeloma
  • +1 moreTrack every material event for Arcellx, Inc. as it happens. Explore monitoring →
Get alerted when Arcellx, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

CAR-T Cell Therapy PlatformOff-the-shelf allogeneic CAR-T therapies→CAR-T and Gene TherapyNon-viral gene editing platform for cell therapies→CAR-T PortfolioEstablished pharma competitor in oncology and CAR-T→

Compare Arcellx, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Arcellx, Inc. operates in Biotechnology - Immunotherapy / Cell Therapy. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Immunotherapy / Cell Therapy research →
NEW · MCP server

Ask your AI assistant about Arcellx, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Arcellx, Inc. and its top competitor on Cyborg Score”
“What did Arcellx, Inc. do this quarter?”
“Is Arcellx, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Arcellx, Inc. do?+
Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. The company's core innovation centers on its ...
What is Arcellx, Inc.'s Cyborg Score?+
Arcellx, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Arcellx, Inc.'s main competitors?+
Named competitors include CAR-T Cell Therapy Platform, CAR-T and Gene Therapy, CAR-T Portfolio. The full competitive landscape is in the AskCyborg report.
How can I get the full Arcellx, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Arcellx, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Arcellx, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Immunotherapy research

Companies in the same sector and named competitors, ranked by Cyborg Score.

6Immutep Limited5TScan Therapeutics, Inc.